Triple Negative Breast Cancer Clinical Trials in San Francisco, California

9 studies are recruiting for triple negative breast cancer in San Francisco, California right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

1. Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012)

   This is a randomized, open-label study comparing the efficacy and safety of adjuvant sacituzumab tirumotecan (MK-2870) in combination with pembrolizumab compared to treatment of physician's choice (TPC) in participants with triple-negative breast cancer (TNBC) who received neoadjuvant therapy and d…

   Stage

   Phase 3

   Ages

   18 and older

   Site

   Kaiser Permanente - San Francisco ( Site 0080), San Francisco, California

   Locations

   311 in total

   Run by

   Merck Sharp & Dohme LLC

   See if you can join NCT06393374 on ClinicalTrials.gov

2. Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63)

   The goal of this study is to find out if the experimental product, sacituzumab govitecan-hziy (SG) in combination with pembrolizumab given after surgery, is effective and safe compared to the treatment of physician's choice (TPC) which includes either pembrolizumab or pembrolizumab plus capecitabin…

   Stage

   Phase 3

   Ages

   18 and older

   Site

   City of Hope (Duarte), San Francisco, California

   Locations

   372 in total

   Run by

   Gilead Sciences

   See if you can join NCT05633654 on ClinicalTrials.gov

3. Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400

   Cancer is a condition where cells in a specific part of body grow and reproduce uncontrollably. The purpose of this study is to assess adverse events and change in disease activity when ABBV-400 is given to adult participants to treat advanced solid tumors. ABBV-400 is an investigational drug being…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   UCSF Medical Center - Mount Zion /ID# 257705, San Francisco, California

   Locations

   54 in total

   Run by

   AbbVie

   See if you can join NCT06084481 on ClinicalTrials.gov

4. A Study of Emiltatug Ledadotin (Emi-Le) in Participants With Solid Tumors

   A Study of Emi-Le in Participants with Solid Tumors

   Stage

   Phase 1

   Ages

   18 and older

   Site

   UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, California

   Locations

   26 in total

   Run by

   Day One Biopharmaceuticals, Inc.

   See if you can join NCT05377996 on ClinicalTrials.gov

5. ARX788 for Treating Patients With HER2-low Locally Advanced Unresectable or Metastatic Breast Cancer

   This phase II trial tests how well ARX788 works in treating patients diagnosed with HER2-low, locally advanced unresectable or metastatic breast cancer. ARX788 is an antibody-drug conjugate (ADC) that is given by infusion (diluted and injected slowly into veins). Antibodies are proteins which are n…

   Stage

   Phase 2

   Ages

   18 and older

   Site

   University of California, San Francisco, San Francisco, California

   Run by

   Laura Huppert, MD, BA

   See if you can join NCT06224673 on ClinicalTrials.gov

6. Atezolizumab + Sacituzumab Govitecan to Prevent Recurrence in TNBC (ASPRIA)

   The purpose of this study is to determine if a combination of two drugs sacituzumab govitecan and atezolizumab works as a treatment for residual cancer in the breast or lymph nodes and have circulating tumor DNA in the blood. This research study involves the following investigational drugs: * Sacit…

   Stage

   Phase 2

   Ages

   18 and older

   Site

   University of California San Francisco, San Francisco, California

   Locations

   7 in total

   Run by

   Dana-Farber Cancer Institute

   See if you can join NCT04434040 on ClinicalTrials.gov

7. A Study With NKT3964 for Adults With Advanced/Metastatic Solid Tumors

   The goal of the Dose Escalation phase of the study is to evaluate the safety, tolerability, pharmacokinetics (PK) and preliminary anti-tumor activity to determine the preliminary recommended dose for expansion (RDE) of NKT3964 in adults with advanced or metastatic solid tumors. The goal of the Expa…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   UCSF, San Francisco, California

   Locations

   19 in total

   Run by

   NiKang Therapeutics, Inc.

   See if you can join NCT06586957 on ClinicalTrials.gov

8. A Beta-only IL-2 ImmunoTherapY Study

   This is a Phase 1/2, multi-center, open-label, dose-escalation and expansion study to evaluate safety and tolerability, PK, pharmacodynamic, and early signal of anti-tumor activity of MDNA11 alone or in combination with a checkpoint inhibitor in patients with advanced solid tumors.

   Stage

   Phase 1

   Ages

   18 and older

   Site

   UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, California

   Locations

   27 in total

   Run by

   Medicenna Therapeutics, Inc.

   See if you can join NCT05086692 on ClinicalTrials.gov

9. A Multicenter Cancer Biospecimen Collection Study

   This study will collect de-identified tumor samples, with correlated clinical/demographic data and tissue histology, from patients selected or scheduled for pre-treatment tumor biopsy or who have had a recent pre-treatment tumor biopsy. These specimens and clinical data may be used in subsequent st…

   Stage

   Not phased

   Ages

   18 and older

   Site

   Curebase, San Francisco, California

   Run by

   Cofactor Genomics, Inc.

   See if you can join NCT04510129 on ClinicalTrials.gov